Search

Displaying results 4191 - 4200 of 10000 in total
  1. Target

    DNA gyrase subunit A

    go.drugbank.com/bio_entities/BE0008382
    TargetEscherichia coli (strain K12)

    A type II topoisomerase that negatively supercoils closed circular double-stranded (ds) DNA in an ATP-dependent manner to maintain chromosomes in an underwound state (PubMed:12051842, PubMed:18642932,

    Polypeptides: DNA gyrase subunit A
  2. Target

    DNA gyrase subunit A

    go.drugbank.com/bio_entities/BE0008385
    TargetStaphylococcus aureus

    A type II topoisomerase that negatively supercoils closed circular double-stranded (ds) DNA in an ATP-dependent manner to modulate DNA topology and maintain chromosomes in an underwound state.

    Polypeptides: DNA gyrase subunit A
  3. Target

    Repulsive guidance molecule A

    go.drugbank.com/bio_entities/BE0018257
    TargetHumans

    It also functions as a bone morphogenetic protein (BMP) coreceptor that may signal through SMAD1, SMAD5, and SMAD8

    Polypeptides: Repulsive guidance molecule ASynonyms: RGM domain family member A
  4. Target

    Poly(A) polymerase gamma

    go.drugbank.com/bio_entities/BE0018981
    TargetHumans

    Responsible for the post-transcriptional adenylation of the 3'-terminal of mRNA precursors and several small RNAs including signal recognition particle (SRP) RNA, nuclear 7SK RNA, U2 small nuclear RNA, and ribosomal 5S RNA

    Polypeptides: Poly(A) polymerase gammaSynonyms: Neo-poly(A) polymerase
  5. Drug

    Iron sucrose

    go.drugbank.com/drugs/DB09146
    ApprovedInvestigational

    Iron sucrose (sucroferric oxyhydroxide or iron saccharate) is used as a source of iron in patients with iron deficiency anemia with chronic kidney disease (CKD), including those who are undergoing dialysis … Due to less side effects than iron dextran, iron sucrose is more preferred in chronic kidney disease patients.

    Mixtures: Marnatal FInternational brands: Ferosoft S
  6. Drug

    Theophylline

    go.drugbank.com/drugs/DB00277
    ApprovedInvestigational

    Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. … A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities.

    Mixtures: TUSBRON-A JARABE, Theophylline 0.8mg/ml In 5% Dextrose InjCategories: Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index
  7. Target

    Lipid A palmitoyltransferase PagP

    go.drugbank.com/bio_entities/BE0001965
    TargetEscherichia coli (strain K12)

    Transfers a palmitate residue from the sn-1 position of a phospholipid to the N-linked hydroxymyristate on the proximal unit of lipid A or its precursors.

    Polypeptides: Lipid A palmitoyltransferase PagPSynonyms: Lipid A acylation protein
  8. Target

    Dihydroorotate dehydrogenase A (fumarate)

    go.drugbank.com/bio_entities/BE0002008
    TargetLactococcus lactis subsp. cremoris

    Catalyzes the conversion of dihydroorotate to orotate with fumarate as the electron acceptor.

    Polypeptides: Dihydroorotate dehydrogenase A (fumarate)Synonyms: DHOD A
  9. Target

    Group A nerve fibers

    go.drugbank.com/bio_entities/BE0009708
    TargetRat

  10. Target

    BCL11 transcription factor A

    go.drugbank.com/bio_entities/BE0019545
    TargetHumans

    May function as a modulator of the transcriptional repression activity of NR2F2 (By similarity) … May play a role in hematopoiesis (By similarity). Essential factor in lymphopoiesis required for B-cell formation in fetal liver (By similarity).

    Polypeptides: BCL11 transcription factor A